CA2510227C - A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis - Google Patents

A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis Download PDF

Info

Publication number
CA2510227C
CA2510227C CA2510227A CA2510227A CA2510227C CA 2510227 C CA2510227 C CA 2510227C CA 2510227 A CA2510227 A CA 2510227A CA 2510227 A CA2510227 A CA 2510227A CA 2510227 C CA2510227 C CA 2510227C
Authority
CA
Canada
Prior art keywords
virus
cancer
cells
echovirus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2510227A
Other languages
English (en)
French (fr)
Other versions
CA2510227A1 (en
Inventor
Darren Shafren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Viralytics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viralytics Ltd filed Critical Viralytics Ltd
Publication of CA2510227A1 publication Critical patent/CA2510227A1/en
Application granted granted Critical
Publication of CA2510227C publication Critical patent/CA2510227C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2510227A 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis Expired - Fee Related CA2510227C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002953436 2002-12-18
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
PCT/AU2003/001688 WO2004054613A1 (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Publications (2)

Publication Number Publication Date
CA2510227A1 CA2510227A1 (en) 2004-07-01
CA2510227C true CA2510227C (en) 2015-03-31

Family

ID=30004521

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2510227A Expired - Fee Related CA2510227C (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Country Status (11)

Country Link
US (2) US7485292B2 (enExample)
EP (1) EP1581257B1 (enExample)
JP (2) JP2006517189A (enExample)
KR (1) KR101171295B1 (enExample)
CN (2) CN1784242B (enExample)
AU (1) AU2002953436A0 (enExample)
CA (1) CA2510227C (enExample)
ES (1) ES2463678T3 (enExample)
NZ (1) NZ541230A (enExample)
WO (1) WO2004054613A1 (enExample)
ZA (1) ZA200505389B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
CN102166218A (zh) * 2005-01-17 2011-08-31 溶瘤病毒有限公司 治疗肿瘤的方法和组合物
WO2013157648A1 (ja) 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
EP2826856B9 (en) 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
MX428707B (es) 2016-09-27 2025-11-13 Sator Therapeutics LLC Virus oncoliticos optimizados y usos de los mismos.
WO2018182014A1 (ja) 2017-03-31 2018-10-04 久修 緒方 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
WO1990012087A1 (en) 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2115991A1 (en) 1991-06-24 1993-01-07 Eckard Wimmer De novo cell-free synthesis of picornavirus
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
US6060316A (en) 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
EP1150696B1 (en) 1999-02-05 2006-05-10 Arch Development Corporation Genetically engineered herpes virus for the treatment of tumours
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
WO2001036650A2 (en) 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020071832A1 (en) 2000-06-01 2002-06-13 Yuman Fong Use of mutant herpes viruses and anticancer agents in the treatment of cancer
WO2002043647A2 (en) 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
US20020146828A1 (en) * 2001-01-05 2002-10-10 John Hural Microparticles and methods for delivery of recombinant viral vaccines
WO2002087625A1 (en) 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP2140879A1 (en) 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
JP2004536607A (ja) 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
AU2003216502B2 (en) 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
WO2003082200A2 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
NZ536102A (en) 2002-05-09 2008-01-31 Oncolytics Biotech Inc Oncolytic viruses, in particular reovirus, for reducing pain associated with proliferative disorders, particularly with the growth of a solid tumour mass
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
DK1668025T3 (da) 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
CN101027394A (zh) 2004-03-11 2007-08-29 维若塔歌私人有限公司 修饰的溶瘤病毒
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006047301A2 (en) 2004-10-21 2006-05-04 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Also Published As

Publication number Publication date
HK1082194A1 (en) 2006-06-02
JP2006517189A (ja) 2006-07-20
AU2002953436A0 (en) 2003-01-09
ZA200505389B (en) 2006-09-27
KR20050115859A (ko) 2005-12-08
US20060134778A1 (en) 2006-06-22
CN1784242A (zh) 2006-06-07
US7485292B2 (en) 2009-02-03
KR101171295B1 (ko) 2012-08-07
EP1581257A1 (en) 2005-10-05
US20100062020A1 (en) 2010-03-11
EP1581257B1 (en) 2014-04-30
ES2463678T3 (es) 2014-05-28
CN102166228B (zh) 2014-02-19
EP1581257A4 (en) 2007-10-17
WO2004054613A1 (en) 2004-07-01
CA2510227A1 (en) 2004-07-01
CN1784242B (zh) 2011-06-08
HK1157657A1 (en) 2012-07-06
CN102166228A (zh) 2011-08-31
NZ541230A (en) 2008-04-30
JP2012046489A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
US20100062020A1 (en) Method of Treating a Malignancy in a Subject Via Direct Picornaviral-Mediated Oncolysis
Au et al. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21
Grote et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice
Shafren et al. Oncolysis of human ovarian cancers by echovirus type 1
Pawlik et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus
Berry et al. Potent oncolytic activity of human enteroviruses against human prostate cancer
US8722036B2 (en) Methods for treating malignancies using coxsackieviruses
KR20060131975A (ko) 변형된 종양 용해 바이러스
CN101132798B (zh) 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物
AU2003287773B2 (en) A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
HK1082194B (en) Composition comprising echovirus ev1 and its use
HK1157657B (en) A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
AU770517B2 (en) A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
Biotech LOW PATHOGENIC HUMAN ENTEROVIRUSES AS NOVEL ANTI-CANCER AGENTS AGAINST MALIGNANT GLIOMA
AU2015230743A1 (en) A method of treating a malignancy in a subject and a pharmaceutical composition for use in same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201218